Karunya Kandimalla to Humans
This is a "connection" page, showing publications Karunya Kandimalla has written about Humans.
Connection Strength
0.618
-
Nelson D, Thompson KJ, Wang L, Wang Z, Eberts P, Azarin SM, Kalari KR, Kandimalla KK. Pericyte Control of Gene Expression in the Blood-Brain Barrier Endothelium: Implications for Alzheimer's Disease. J Alzheimers Dis. 2024; 99(s2):S281-S297.
Score: 0.044
-
Wang Z, Sharda N, Omtri RS, Li L, Kandimalla KK. Amyloid-Beta Peptides 40 and 42 Employ Distinct Molecular Pathways for Cell Entry and Intracellular Transit at the Blood-Brain Barrier Endothelium. Mol Pharmacol. 2023 Nov; 104(5):203-213.
Score: 0.043
-
Wang L, Wiedmann TS, Kandimalla KK. Modulating insulin signaling and trafficking at the blood-brain barrier endothelium using lipid based nanoemulsions. Int J Pharm. 2022 Jun 25; 622:121823.
Score: 0.039
-
Wang Z, Sharda N, Curran GL, Li L, Lowe VJ, Kandimalla KK. Semimechanistic Population Pharmacokinetic Modeling to Investigate Amyloid Beta Trafficking and Accumulation at the BBB Endothelium. Mol Pharm. 2021 11 01; 18(11):4148-4161.
Score: 0.038
-
Salian VS, Wright JA, Vedell PT, Nair S, Li C, Kandimalla M, Tang X, Carmona Porquera EM, Kalari KR, Kandimalla KK. COVID-19 Transmission, Current Treatment, and Future Therapeutic Strategies. Mol Pharm. 2021 03 01; 18(3):754-771.
Score: 0.036
-
Sharda N, Ahlschwede KM, Curran GL, Lowe VJ, Kandimalla KK. Distinct Uptake Kinetics of Alzheimer Disease Amyloid-? 40 and 42 at the Blood-Brain Barrier Endothelium. J Pharmacol Exp Ther. 2021 03; 376(3):482-490.
Score: 0.036
-
Sharda N, Pengo T, Wang Z, Kandimalla KK. Amyloid-? Peptides Disrupt Interactions Between VAMP-2 and SNAP-25 in Neuronal Cells as Determined by FRET/FLIM. J Alzheimers Dis. 2020; 77(1):423-435.
Score: 0.033
-
Zhou AL, Swaminathan SK, Curran GL, Poduslo JF, Lowe VJ, Li L, Kandimalla KK. Apolipoprotein A-I Crosses the Blood-Brain Barrier through Clathrin-Independent and Cholesterol-Mediated Endocytosis. J Pharmacol Exp Ther. 2019 06; 369(3):481-488.
Score: 0.032
-
Ahlschwede KM, Curran GL, Rosenberg JT, Grant SC, Sarkar G, Jenkins RB, Ramakrishnan S, Poduslo JF, Kandimalla KK. Cationic carrier peptide enhances cerebrovascular targeting of nanoparticles in Alzheimer's disease brain. Nanomedicine. 2019 02; 16:258-266.
Score: 0.031
-
Swaminathan SK, Fisher J, Brogden NK, Kandimalla KK. Development and validation of a sensitive LC-MS/MS method for the estimation of scopolamine in human serum. J Pharm Biomed Anal. 2019 Feb 05; 164:41-46.
Score: 0.031
-
Omtri RS, Thompson KJ, Tang X, Gali CC, Panzenboeck U, Davidson MW, Kalari KR, Kandimalla KK. Differential Effects of Alzheimer's Disease A?40 and 42 on Endocytosis and Intraneuronal Trafficking. Neuroscience. 2018 03 01; 373:159-168.
Score: 0.029
-
Swaminathan SK, Ahlschwede KM, Sarma V, Curran GL, Omtri RS, Decklever T, Lowe VJ, Poduslo JF, Kandimalla KK. Insulin differentially affects the distribution kinetics of amyloid beta 40 and 42 in plasma and brain. J Cereb Blood Flow Metab. 2018 05; 38(5):904-918.
Score: 0.028
-
Agyare EK, Jaruszewski KM, Curran GL, Rosenberg JT, Grant SC, Lowe VJ, Ramakrishnan S, Paravastu AK, Poduslo JF, Kandimalla KK. Engineering theranostic nanovehicles capable of targeting cerebrovascular amyloid deposits. J Control Release. 2014 Jul 10; 185:121-9.
Score: 0.022
-
Jaruszewski KM, Curran GL, Swaminathan SK, Rosenberg JT, Grant SC, Ramakrishnan S, Lowe VJ, Poduslo JF, Kandimalla KK. Multimodal nanoprobes to target cerebrovascular amyloid in Alzheimer's disease brain. Biomaterials. 2014 Feb; 35(6):1967-76.
Score: 0.022
-
Kandimalla KK, Borden E, Omtri RS, Boyapati SP, Smith M, Lebby K, Mulpuru M, Gadde M. Ability of chitosan gels to disrupt bacterial biofilms and their applications in the treatment of bacterial vaginosis. J Pharm Sci. 2013 Jul; 102(7):2096-101.
Score: 0.021
-
Agyare EK, Leonard SR, Curran GL, Yu CC, Lowe VJ, Paravastu AK, Poduslo JF, Kandimalla KK. Traffic jam at the blood-brain barrier promotes greater accumulation of Alzheimer's disease amyloid-? proteins in the cerebral vasculature. Mol Pharm. 2013 May 06; 10(5):1557-65.
Score: 0.021
-
Poduslo JF, Howell KG, Olson NC, Ramirez-Alvarado M, Kandimalla KK. Alzheimer's disease amyloid ?-protein mutations and deletions that define neuronal binding/internalization as early stage nonfibrillar/fibrillar aggregates and late stage fibrils. Biochemistry. 2012 May 15; 51(19):3993-4003.
Score: 0.020
-
Jaruszewski KM, Ramakrishnan S, Poduslo JF, Kandimalla KK. Chitosan enhances the stability and targeting of immuno-nanovehicles to cerebro-vascular deposits of Alzheimer's disease amyloid protein. Nanomedicine. 2012 Feb; 8(2):250-60.
Score: 0.019
-
Kandimalla KK, Wengenack TM, Curran GL, Gilles EJ, Poduslo JF. Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice. J Pharmacol Exp Ther. 2007 Aug; 322(2):541-9.
Score: 0.014
-
Kandimalla KK, Curran GL, Holasek SS, Gilles EJ, Wengenack TM, Ramirez-Alvarado M, Poduslo JF. Physiological and biophysical factors that influence Alzheimer's disease amyloid plaque targeting of native and putrescine modified human amyloid beta40. J Pharmacol Exp Ther. 2006 Jul; 318(1):17-25.
Score: 0.013
-
Kandimalla KK, Curran GL, Holasek SS, Gilles EJ, Wengenack TM, Poduslo JF. Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation. J Pharmacol Exp Ther. 2005 Jun; 313(3):1370-8.
Score: 0.012
-
Wang Z, Tang X, Swaminathan SK, Kandimalla KK, Kalari KR. Mapping the dynamics of insulin-responsive pathways in the blood-brain barrier endothelium using time-series transcriptomics data. NPJ Syst Biol Appl. 2022 08 16; 8(1):29.
Score: 0.010
-
Gali CC, Fanaee-Danesh E, Zandl-Lang M, Albrecher NM, Tam-Amersdorfer C, Stracke A, Sachdev V, Reichmann F, Sun Y, Avdili A, Reiter M, Kratky D, Holzer P, Lass A, Kandimalla KK, Panzenboeck U. Amyloid-beta impairs insulin signaling by accelerating autophagy-lysosomal degradation of LRP-1 and IR-? in blood-brain barrier endothelial cells in vitro and in 3XTg-AD mice. Mol Cell Neurosci. 2019 09; 99:103390.
Score: 0.008
-
Thompson KJ, Ingle JN, Tang X, Chia N, Jeraldo PR, Walther-Antonio MR, Kandimalla KK, Johnson S, Yao JZ, Harrington SC, Suman VJ, Wang L, Weinshilboum RL, Boughey JC, Kocher JP, Nelson H, Goetz MP, Kalari KR. A comprehensive analysis of breast cancer microbiota and host gene expression. PLoS One. 2017; 12(11):e0188873.
Score: 0.007
-
Ramakrishnan M, Wengenack TM, Kandimalla KK, Curran GL, Gilles EJ, Ramirez-Alvarado M, Lin J, Garwood M, Jack CR, Poduslo JF. Selective contrast enhancement of individual Alzheimer's disease amyloid plaques using a polyamine and Gd-DOTA conjugated antibody fragment against fibrillar Abeta42 for magnetic resonance molecular imaging. Pharm Res. 2008 Aug; 25(8):1861-72.
Score: 0.004
-
Poduslo JF, Ramakrishnan M, Holasek SS, Ramirez-Alvarado M, Kandimalla KK, Gilles EJ, Curran GL, Wengenack TM. In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques. J Neurochem. 2007 Jul; 102(2):420-33.
Score: 0.004
-
Holasek SS, Wengenack TM, Kandimalla KK, Montano C, Gregor DM, Curran GL, Poduslo JF. Activation of the stress-activated MAP kinase, p38, but not JNK in cortical motor neurons during early presymptomatic stages of amyotrophic lateral sclerosis in transgenic mice. Brain Res. 2005 May 31; 1045(1-2):185-98.
Score: 0.003